Aims: To evaluate possible differences in effect on time to recurrence and overall survival in node positive premenopausal breast cancer patients (age 50 years) receiving LHRH analogue or tamoxifen as adjuvant endocrine treatment. Methods: Between January 1989 and July 1994, 320 patients with node positive (pN ) and hormone receptor positive or receptor status unknown tumors were included and randomized in a national multicenter study to receive either tamoxifen or goserelin as adjuvant treatment for two years. Primary surgical treatment was employed according to current standards. Final follow-up was completed as of December 2000. Time to events were estimated by the Kaplan±Meier method, and compared by the log rank test. Relative risks were estimated by the Cox's proportional hazards model. Results: No differences in time to first recurrence or overall survival were observed between treatment groups. Proportions of patients in each group having a second breast cancer were also similar. Conclusions: Standard adjuvant treatment with tamoxifen as compared to adjuvant LHRH analogue therapy employed in this group of breast cancer patients gave similar outcomes, but the number of patients was too small to formally exclude a potentially clinically relevant difference in survival.
INTRODUCTION
In the mid 1970's the first reports focusing on systemic adjuvant treatment of patients with operable breast cancer appeared. 1±3 In order to draw appropriate conclusions based on available clinical observations, data were collected from trial groups all over the world. 4 An overall survival benefit was demonstrated for all patients receiving either tamoxifen or polychemotherapy.
Adjuvant treatment with tamoxifen had a significant effect in postmenopausal patients (b 50 years of age group), reducing the risk of death by approximately 20%, but had very little effect in the younger age group. 5, 6 However, the majority of younger women also received adjuvant chemotherapy. 6 From the overview analysis 4 it was apparent that risk of death decreased significantly in women under 50 years who were treated with ovarian ablation (i.e. ovarian irradiation or surgical oophorectomy). For many patients, these techniques of ovarian ablation were associated with distressing morbidity. Both patients and clinicians had concerns regarding the use of these modalities in an adjuvant situation. Trials on breast cancer patients with advanced disease using compounds that produced a reversible chemical castration were instigated in the mid 1980s, and in 1986 a promising report on the response to a LHRH agonist (ICI 118,630) in premenopausal breast cancer patients with advanced disease was published. 7 A wide range of treatment policies were employed on early breast cancer patients at that time. 8 This was mostly because of lack of evidence of any survival advantage between the various treatment policies. Early results using LHRH agonists in advanced breast cancer disease were regarded as promising. 7 Compared to castration by irradiation or surgery, results were achieved with little toxicity and side effects. Based on these observations, and encouraged by current discussions on various adjuvant trials at the time, including ongoing work within the British Cancer Research Campaign, the present study was designed. Our goal was to address effects on disease-free and overall survival of two different adjuvant endocrine treatment options (LHRH agonist vs tamoxifen) randomly offered to a well defined group of premenopausal patients with operable (stage II, node positive) breast cancer disease, with estrogen receptor (ER) or progesterone receptor (PgR) positive tumours, or tumours with receptor status unknown.
MATERIAL AND METHODS

Patients
Between January 1989 and July 1994, 320 premenopausal (defined as age 50 years) women with operable breast cancer stage II (pN ) were included and randomized in this prospective adjuvant study. Median age of the study population was 45 years, and main clinical characteristics are shown in Table 1 . The Regional Committee of Ethics approved the study protocol, and informed consent was obtained from all patients included.
Surgical treatment
The patients were surgically treated in 41 hospitals, and 20% of the patients in both groups completed breast conservation treatment that included routine postoperative radiotherapy to the breast (Table 2) . Axillary dissection (levels I II) was performed. Nine of the participating hospitals treated at least 10 patients, and half of the study population was treated at four hospitals.
During the period of inclusion, all surgically treated breast cancer patients , 70 years of age were offered a standard perioperative adjuvant chemotherapy treatment. On day 0, an intravenous course comprising 1 mg vincristin, 400 mg cyclophosphamide and 500 mg 5-fluorouracil was given, and repeated on day 7 with cyclophosphamide replaced by 50 mg methotrexate. Most patients included in our study received this standard perioperative chemotherapy ( Table 2 ).
Randomization and adjuvant endocrine treatment
The randomization was taken care of by telephone to the study center. It was performed as a block randomization with block size six, and each participating hospital represented a stratum. Patients were allocated to receive either tamoxifen (TAM; Nolvadex TM ) 20 mg daily or goserelin (LHRH agonist; Zoladex TM ) given as 3.6 mg depot injected subcutaneously into the anterior abdominal wall once every 28 days by prefilled applicator. Adjuvant treatment was continued for two years, or until first confirmation of recurrent disease.
Primary tumor-, nodal status and hormone receptors TNM classification was done according to UICC criteria. 9 Distribution of pT classification, size and grade as well as nodal status between the two treatment groups is shown in Table 3 . Hormone receptors were measured as reported previously. 10 Estrogen receptor (ER) or progesterone receptor (PgR) levels above 10 fmol/mg protein were criteria for hormone receptor positivity. This study also included tumors with unknown 11 (7) 17 (11) * All patients were pN . receptor status. However, tumors with ER or PgR , 10 fmol/mg were regarded hormone receptor negative, and patients with known receptor negative tumours at the time of randomization were not included. No difference regarding receptor status or content between the two treatment arms was observed (Table 4) .
Follow-up
Patients were followed-up by clinical examination every 3rd month for two years, then every 6th month up to three years and thereafter on an annual basis. A clinical follow-up form was completed on every visit. Initial sites of loco-regional recurrence or distant metastases were recorded when confirmed. Confirmation was made as follows:
Chest wall or regional nodes ± by cytology or histology whenever possible.
Skeletal ± conventional radiology, or bone scan. Pulmonary ± chest X-ray, or computer tomography (CT) when appropriate. Hepatic ± ultrasound and/or CT, confirmed by cytology (FNAC) when necessary.
A novel breast cancer was defined as a new malignant tumour in the contralateral breast, or a new malignant tumour located in a different quadrant of the ipsilateral breast in patients previously treated with breast conservation.
A final follow-up was completed as of December 2000.
Statistics
The primary end-point was time to first recurrence. The study was designed to have 90% power to detect a 15% absolute difference in the proportion of patients with recurrence at five years (45% vs 30%). With inclusion of patients over five years and a minimum follow-up of seven years, it was estimated that a total of 320 patients should be included. With this patient number, the probability of detecting a 10% difference should it exist, will be approximately 65%. Although it might have been of interest to detect smaller differences in treatment effect, a larger study was considered impracticable since the patient inclusion period would then exceed 5 years. Time to recurrence was calculated from randomization to recurrence. Patients with no recurrence were censored at the time of death or end of observation alive. Secondary end-points were overall survival and time to diagnosis of a novel malignant breast tumour. Overall survival was calculated from randomization to death of any cause. In the analysis of time to a new breast tumour, patients were treated as censored at the end of observation (dead or alive) in cases where this event did not occur. Time to each event (as specified above) was estimated by the Kaplan±Meier method, and the two treatment groups were compared by the log rank test. Relative hazards (relative risks) were estimated by Cox's proportional hazards model.
A pre-planned interim analysis was performed in November 1997. O'Brien and Fleming stopping rules were applied, 11 and no significant difference between treatments was found (P . 0.0051). In order to maintain an overall significance level of 5%, a nominal level of P 0.0475 was thus to be used for this second and final analysis.
RESULTS
The median follow-up time for all patients was 88 months, and for patients still alive the median follow-up time was 96 (range, 23±139) months. Figure 1 shows (Table 5 ).
DISCUSSION
No difference between treatment groups regarding time to first recurrence or overall survival was observed in our study. This does not imply that we have documented equivalent effects of the two treatments. The sample size is too small for such a conclusion to be drawn, which is illustrated by the width of the confidence intervals presented; The 95% confidence interval (95% CI, 0.80±1.49) for the relative risk of recurrence is consistent with a potential relative increase in risk of 49% with LHRH compared to TAM, but also with a relative reduction in risk by TAM of 20%. A small, but possible clinically important, difference in either direction can therefore not be excluded. Treatment groups were well balanced by randomization with regard to patient characteristics, pT classification and grade, receptor status and primary treatment. There was a small difference between groups in proportions of patients treated with perioperative adjuvant chemotherapy. Results remained unchanged n.s. Figure 1 Time to first recurrence for the TAM group ( ) compared to the LHRH group ( ). Number of patients still at risk at 5, 8, and 10 years were 98, 45, and 9 (TAM group) and 87, 35, 9 (LHRH group). n.s. non significant. Figure 2 Overall survival for TAM group ( ) and LHRH group ( ). Number of patients still at risk at 5, 8, and 10 years were 122, 60, and 16 (TAM group) and 119, 60, and 17 (LHRH group). n.s. non significant.
Proportion of recurrences
Proportion of second breast cancers n.s. Figure 3 Time to second breast cancer for TAM group ( ) and LHRH group ( ). Patients still at risk at 5, 8, and 10 years were 118, 57, and 13 (TAM group) and 117, 56, and 14 (LHRH group). n.s. non significant. when adjusting for this difference. For a number of patients receptor status and grade was unknown. Since patients were randomized between treatments receptor status and grade are expected to be equally distributed in the two treatment groups, and missing values do not affect the main statistical analysis.
A very high proportion of the eligible premenopausal breast cancer patients in Norway during the recruitment period was included in our study, which therefore comes close to being a true population based study. 12 This fact strengthens the relevance of the results.
The observed median disease free survival of 87 months in our study population of node positive patients compares well with other reports. 13 The number and locations of first events and relapses are also as expected. There was no statistical significant difference between the two treatment groups regarding new ipsior contralateral cancers. At last follow-up about onethird of the patients were deceased, and an estimated 5-year survival of 78% for our study population comprising high risk node positive breast cancer patients is as expected.
The role and importance of adjuvant endocrine treatment in breast cancer management has been addressed in several studies, and treatment choices have been made based on presence and degree of expression of estrogen receptor (ER) and progesterone receptor (PgR) as well as clinical parameters.
14 In a previous randomized study, we found adjuvant tamoxifen treatment to be of benefit only for postmenopausal women with ER positive tumours. 15 According to an overview on randomized trials with adjuvant tamoxifen for early breast cancer, 13 some years (i.e. preferably 5 years) of adjuvant tamoxifen treatment substantially improves the 10-year survival of women with ERpositive tumors and of women whose tumors are of unknown ER status. The reduction in mortality appeared to be largely unaffected by other patient characteristics and treatment, including menopausal status, age and chemotherapy.
Systemic treatment of premenopausal women with breast cancer has been targeted at removal of the main source of estrogen biosynthesis, including surgical oophorectomy, ovarian irradiation, and more recently, chemical castration by LHRH agonist therapy. However, the optimal means to achieve the most favorable effect in a clinical setting remain unclear. 16 Based on the observation that a large proportion of premenopausal patients lost their menstruation during adjuvant chemotherapy treatment for breast cancer, it was speculated if this treatment was sufficient to achieve an endocrine effect on the course of the disease. According to Goldhirsch and coworkers, amenorrhoea develops predominantly in pre-menopausal women receiving prolonged adjuvant chemotherapy. Amenorrhoea was observed in 68% of the patients in this subgroup. 17 In patients who received no adjuvant chemotherapy or a single course with chemotherapy only, amenorrhoea was observed in 21% and 31%, respectively. 17 These observations are supported by earlier reports. 18 It has also been reported the endocrine effects of chemotherapy alone are insufficient for premenopausal patients, and for the younger age group in particular. 19 For these patients additional endocrine therapies should be strongly considered if their tumours express estrogen receptors.
Ovarian ablation by irradiation has been employed in several prospective studies, and in a recent overview on several studies with a 15 years follow up time, this treatment option was regarded effective, at least in the absence of chemotherapy, and long-term survival was improved significantly. 20 Nevertheless, the authors emphasize that further randomized evidence is needed to evaluate the additional effects of ovarian ablation in the presence of other adjuvant treatments, and to assess the relevance of hormone-receptor measurements.
The introduction of an LHRH agonist in the adjuvant treatment of premenopausal women has the advantages of replacing surgical oophorectomy or irradiation menopause by chemical castration. Chemical castration is potentially reversible. The drug is reported to be well tolerated by premenopausal women with advanced breast cancer. 21 In the present study, we did not record details regarding treatment side effects. However, no major concerns in either group were observed or caused premature termination of the adjuvant endocrine treatment. This is in concert with a recent paper, which report on similar symptoms and complaints among patients randomized to receive tamoxifen or LHRH agonist as adjuvant treatment, even though more intense menopausal symptoms were observed in LHRH treated patients. 22 Still, many questions remain to be answered regarding the optimal adjuvant treatment of premenopausal women with early breast cancer. 14, 16, 23, 24 Selection criteria and prognostication, treatment approach, duration and type of treatment are all important topics that need further evaluation. 17, 19, 25, 26 Treatment compliance and evaluation of costs need to be addressed, 27 and contemporary drugs (taxanes, antracyclines, erbB-2 antibodies etc.) in the adjuvant situation have to be evaluated further.
In conclusion, this prospective, randomized population based study of premenopausal women with node positive operable breast cancer, and ER or PgR positive or unknown tumours, with a rather long follow-up time of median 88 months did not reveal any statistically significant difference between two years of adjuvant LHRH or tamoxifen with regard to time to recurrence and overall survival. The number of patients included in this study was too small to formally demonstrate equivalence of the two treatments.
